Vaccines against Meningococcal Diseases

Area of Science:

• * Infectious disease epidemiology and vaccinology.
• * Microbiology and immunology of *Neisseria meningitidis*.

Background:

• * *Neisseria meningitidis* causes meningitis and sepsis, posing significant public health risks.
• * Available vaccines target serogroups A, B, C, W, and Y, with successful disease reduction in specific regions.
• * Shifting epidemiology necessitates broader vaccine coverage, moving towards quadrivalent vaccines.

Purpose of the Study:

• * To review the impact of existing meningococcal vaccines.
• * To highlight the evolution of vaccination strategies from monovalent to quadrivalent vaccines.
• * To discuss the ongoing development of next-generation vaccines for enhanced global control.

Main Methods:

• * Review of vaccination program outcomes and epidemiological trends.
• * Analysis of vaccine effectiveness data for meningococcal serogroups.
• * Examination of research and development in new vaccine formulations.

Main Results:

• * Monovalent MenC and MenA vaccines have drastically reduced disease incidence in Europe and Africa, respectively.
• * Quadrivalent MenACWY vaccines are increasingly recommended for broader protection.
• * Protein-based MenB vaccines demonstrate reassuring real-world effectiveness.

Conclusions:

• * Meningococcal vaccines have greatly improved global health outcomes.
• * Continued surveillance and research into evolving epidemiology are crucial.
• * Next-generation pentavalent vaccines are anticipated to further enhance meningitis control worldwide.